R. Álvarez

Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

M. Provencio, A. Royuela, J. Chacón, 2018, Leukemia & lymphoma.

SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)

A. Arance, J. López-Martín, D. Rodríguez-Abreu, 2020, Clinical and Translational Oncology.

Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice

R. Álvarez, D. Almenar Cubells, C. Bosch Roig, 2013, European journal of cancer care.

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

M. Provencio, M. Torrente, A. Royuela, 2017, Clinical lymphoma, myeloma & leukemia.

Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).

U. Dafni, D. de Ruysscher, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

B. Massuti, V. Calvo, M. Provencio, 2022, JAMA oncology.

Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

F. Carabantes, R. Álvarez, A. Alegre, 2012, Current medical research and opinion.

Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

V. Calvo, M. Provencio, D. Rodríguez-Abreu, 2018, Leukemia & lymphoma.

90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.

A. Royuela, J. Chacón, F. Franco, 2018 .

[Treatment with (131)I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure].

E. Prats, R. Álvarez, J. Banzo, 2010, Revista espanola de medicina nuclear.

[Treatment with (131)I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure].

E. Prats, R. Álvarez, J. Banzo, 2010, Revista espanola de medicina nuclear.

Treatment of thyroid remnants with 131I in a patient with papillary thyroid carcinoma and end-stage chronic renal failure

E. Prats, R. Álvarez, J. Banzo, 2010 .